Shareholder Approval for Strategic Investment by RAMM Pharma
TORONTO -- RAMM Pharma Corp. (CSE: RAMM) is delighted to share that it has received the green light from its minority shareholders for a pivotal investment transaction with The Global South S.A.S. During the recent Special Meeting of Shareholders, this crucial Transaction was set in motion, allowing RAMM to align itself with The Global South effectively.
Details of the Investment Transaction
The approved Transaction entails a significant US$5 million investment in exchange for a 10% equity stake in The Global South S.A.S., which is based on a post-investment valuation of US$50 million. Additionally, RAMM Pharma is granted a call option to acquire an extra 15% equity interest in the future, which could elevate its overall ownership to 25% contingent upon a post-money valuation of US$400 million.
Financing and Transaction Progress
Currently, the company is exploring various financing options to secure the necessary funds for the Transaction. While excitement surrounds this partnership, RAMM emphasizes that the completion of the Transaction also hinges on negotiating definitive agreements and receiving essential regulatory approvals, which is a customary step in such investment dealings.
Understanding RAMM Pharma Corp.
RAMM Pharma specializes in cannabinoid pharmacology and innovative formulations for cannabis-based pharmaceuticals. With a focus on delivering high-quality hemp products, RAMM stands as a dynamic player in the sector with an extensive international production and sales platform.
Operating in Europe and Beyond
In Europe, RAMM has established integrated operations in Italy and Poland, showcasing large extraction and processing facilities. Their subsidiary, Canapar Corp., is pivotal in these operations. Additionally, HemPoland, licensed for production, serves as a contract manufacturer and distributor, representing a diverse portfolio, including the well-known CannabiGold-branded products.
Future Directions and Potential Growth
As RAMM Pharma looks ahead, the company remains committed to expanding its footprint in the global cannabis market. Current dynamics in the medical and recreational cannabis sectors demonstrate considerable growth potential in various regions. This expansion vision, bolstered by recent shareholder support, positions RAMM Pharma strategically for the future.
Strategic Partnerships and Opportunities
Through this partnership with The Global South, RAMM Pharma aims to leverage synergies that could foster innovation and improve efficiency. Such strategic collaborations are essential for accelerating growth and navigating the evolving landscape of the cannabis industry.
Contact Information for RAMM Pharma Corp.
For further inquiries about the Transaction or RAMM Pharma Corp.’s operations, interested parties are encouraged to reach out to José Roldan, Interim CFO. His contact details are +598 95 050 823 or via email at jroldan@rammpharma.com.
Frequently Asked Questions
What is the recent investment transaction RAMM Pharma announced?
RAMM Pharma Corp. has received approval for a US$5 million investment in The Global South S.A.S. for a 10% equity interest.
How will this investment impact RAMM Pharma?
The investment is expected to strengthen RAMM's market position and expand its portfolio in the cannabis sector.
What does the call option entail for RAMM Pharma?
The call option allows RAMM to increase its stake in The Global South S.A.S. by an additional 15%, potentially raising its total ownership to 25%.
Where are RAMM Pharma's operations based?
RAMM Pharma operates in Italy and Poland, focusing on cannabinoid pharmacology and producing hemp-based products.
Who can I contact for more information about RAMM Pharma?
For inquiries, you can contact José Roldan, Interim CFO, at +598 95 050 823 or email at jroldan@rammpharma.com.
